دورية أكاديمية

Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.

التفاصيل البيبلوغرافية
العنوان: Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.
المؤلفون: Lei, Ming, Doki, Yuichiro, Kitagawa, Yuko, Kato, Ken, Chau, Ian, Yao, Jin, Xu, Jianming, Wyrwicz, Lucjan S., Motoyama, Satoru, Ogata, Takashi, Kawakami, Hisato, Hsu, Chih-Hung, Adenis, Antoine, El Hajbi, Farid, Di Bartolomeo, Maria, Braghiroli, Maria Ignez, Holtved, Eva, Blum Murphy, Mariela A., Novosiadly, Ruslan, Ajani, Jaffer A.
المصدر: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p252-252, 185p
قاعدة البيانات: Supplemental Index
الوصف
تدمد:0732183X
DOI:10.1200/JCO.2024.42.3_suppl.252